Loading organizations...
The Oklahoma Life Science Fund (OLSF) is an early-stage venture capital fund that strategically invests in promising life science startups across Oklahoma. The fund primarily targets companies developing disruptive innovations, including novel therapeutics for diseases and advanced medical devices, with a focus on biotech, healthcare, and technology sectors within the state. It employs a rigorous approach to identify and support high-potential ventures poised for significant market impact.
Established in 2000, the fund was created to address the need for dedicated life science and healthcare investment within Oklahoma. It operates through distinct investment funds, such as OLSF I and OLSF II, with its operations managed by individuals like William Paiva. The founding insight recognized a strong enthusiasm for fostering local bioscience companies and attracting broader capital to the region by co-investing with external venture capital firms.
OLSF serves Oklahoma-based bioscience companies and entrepreneurs, providing essential early-stage capital and strategic guidance. The fund's long-term vision is to cultivate and strengthen the state's position as a vibrant hub for life science innovation. By supporting the development of pharmaceuticals, medical devices, and other crucial technologies, OLSF aims to enhance the credibility of Oklahoma's healthcare innovators and establish a clear path for future entrepreneurial success.
Oklahoma Life Science Fund has 5 tracked investments across 4 companies. The latest tracked deal is $2.4M Seed in Cadenza Bio in December 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Dec 14, 2023 | Cadenza Bio | $2.4M Seed | Justin Wilson | Boyd Street Ventures, Cortado Ventures, Illinois Ventures |
| Sep 24, 2020 | Sway Medical | $4.2M Series A | Atento Capital, Oklahoma Life Science Fund | Eric Warren, Will Smith, ADG, Cortado Ventures, Innovation IN Motion, Progeny Plus Capital Partners |
| Apr 4, 2014 | Otologic Pharmaceutics | $4.1M Series A | Richard Gammans | — |
| Jun 1, 2012 | AliveCor | $11.0M Series B | G. Steven Burrill, Vinod Khosla | Qualcomm |
| Aug 23, 2011 | AliveCor | $3.0M Series A | Bryant Fong | Nagraj Kashyap |